journal
https://read.qxmd.com/read/37401422/corrigendum-to-lung-metastasectomy-for-osteosarcoma-in-children-adolescents-and-young-adults-proof-of-permanent-cure
#41
(no author information available yet)
No abstract text is available yet for this article.
August 2023: Tumori
https://read.qxmd.com/read/36756996/duration-of-androgen-deprivation-with-radiotherapy-for-high-risk-or-locally-advanced-prostate-cancer-a-network-meta-analysis
#42
JOURNAL ARTICLE
Fausto Petrelli, Agostina De Stefani, Ivano Vavassori, Federica Motta, Andrea Luciani, Francesca Trevisan
OBJECTIVE: To evaluate various outcomes of different lengths of androgen deprivation therapy in high- and very-high-risk prostate cancer, we conducted a network meta-analysis of randomized trials. The treatment of high-risk PC comprises the use of radical radiotherapy associated with various durations of androgen deprivation therapy, with luteinizing hormone releasing hormone analogues initiated during or immediately before the beginning of radiation. METHODS AND MATERIALS: This study followed the PRISMA extension statement to report network meta-analyses...
August 2023: Tumori
https://read.qxmd.com/read/35815563/central-venous-catheters-related-thrombosis-and-risk-factors-in-oncological-patients-a-retrospective-evaluation-of-recent-risk-scores
#43
JOURNAL ARTICLE
Ida Taglialatela, Luigi Mariani, Katia Fiorella Dotti, Laura Di Vico, Maria Neve Pisanu, Claudia Facchinetti, Filippo De Braud, Laura Anna Maria Ferrari
BACKGROUND: Insertions of central venous catheters (CVC) has become a common practice in Onco-Hematologic Units to administer systemic treatments. Unfortunately they can cause complications influencing patient's care-pathway significantly. Oncological patients have a higher thrombotic risk than the general population, therefore specific recent risk scores are spreading through the clinical practice, such as Khorana, Protecht, COMPASS-CAT, and Michigan scores. METHODS: A retrospective cohort of 177 out of a total of 3046 outpatients accessing the Medical Day Hospital of Istituto Nazionale Tumori di Milano from March 2019 to February 2021 aged ⩾ 18 years who developed CVC complications was analyzed extracting clinical data from their medical records...
August 2023: Tumori
https://read.qxmd.com/read/37501595/role-of-enhancement-modifications-in-evaluating-tumor-response-to-immunotherapy-in-metastatic-renal-cell-carcinoma
#44
JOURNAL ARTICLE
Michele Dionese, Francesco Pierantoni, Elisabetta Bezzon, Enrico Cumerlato, Davide Bimbatti, Umberto Basso, Marco Maruzzo, Vittorina Zagonel
INTRODUCTION: Evaluation of tumor response according only to dimensional criteria may underestimate treatment benefit in patients treated for metastatic renal cell carcinoma (RCC). In this study we evaluated the role of lesion enhancement modifications and Choi criteria in patients affected by renal cell carcinoma treated with immunotherapy. METHODS: We collected data of 60 consecutive patients (with a total of 154 measurable lesions) treated with immunotherapy (nivolumab or ipilimumab plus nivolumab) at a single Institution...
July 28, 2023: Tumori
https://read.qxmd.com/read/37486101/have-we-made-progress-in-taking-care-of-adolescents-and-young-adults-with-cancer-results-of-a-european-multi-professional-survey
#45
JOURNAL ARTICLE
Ivana Bozovic Spasojevic, Andrea Ferrari, Johan De Munter, Ashley Gamble, Assia Konsoulova-Kirova, Katie Rizvi, Carina Schneider, Marie Balsat, Anna Castleton, Leila Gofti-Laroche, Anita Kienesberger, Beate Timmermann, Josef Vormoor, Emmanouil Saloustros, Daniel P Stark
BACKGROUND: It is well documented that traditional health care models do not meet the specific needs of Adolescents and Young Adults (AYA) cancer patients. METHODS: We explore a map of the development of age-specific AYA cancer care across Europe, from the perspective of healthcare professionals with an interest in AYA care, in order to understand the specific challenges and map progress over time. An on-line survey was developed by international professional cancer organisations...
July 24, 2023: Tumori
https://read.qxmd.com/read/37434559/current-practices-of-follow-up-programs-for-childhood-cancer-survivors-in-italy
#46
JOURNAL ARTICLE
Monica Terenziani, Alberto Eugenio Tozzi, Laura Diaco, Eleonora Biasin, Alessandro Cattoni, Ileana Croci, Donatella Fraschini, Giovanna Giorgiani, Riccardo Haupt, Monica Muraca, Marta Pillon, Giovanna Sironi, Maria Grazia Valsecchi, Angela Mastronuzzi
INTRODUCTION: Quality of life in childhood cancer survivors is largely affected by survivorship care and transition from treatment to long-term follow-up (LTFU). Referring to evidence-based recommendations, we wanted to evaluate LTFU care for survivors through a survey among the Italian Association for Pediatric Hematology-Oncology (AIEOP) centers. The project aimed to evaluate the availability of services in Italy, investigate strengths and weaknesses, analyze improvements of awareness in the field, and identify the gaps that need to be addressed by different centers...
July 12, 2023: Tumori
https://read.qxmd.com/read/37417313/outcomes-in-patients-with-braf-v600-mutated-melanoma-and-brain-metastases-at-baseline-treated-with-dabrafenib-plus-trametinib
#47
JOURNAL ARTICLE
Massimo Aglietta, Vanna Chiarion-Sileni, Paolo Fava, Massimo Guidoboni, Roberta Depenni, Alessandro Minisini, Francesca Consoli, Paolo Antonio Ascierto, Gaetana Rinaldi, Maria Banzi, Riccardo Marconcini, Rossana Gueli, Virginia Ferraresi, Marco Tucci, Giuseppe Tonini, Giovanni Lo Re, Michele Guida, Michele Del Vecchio, Ilaria Gioia Marcon, Paola Queirolo
BACKGROUND: Brain metastases (BM) and lactate dehydrogenase (LDH) levels above the upper limit of normal (ULN) are associated with poor prognosis in patients with melanoma. Although treatment with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib have demonstrated long-term clinical benefit in patients with melanoma, data on their efficacy in patients with BM are limited. METHODS: DESCRIBE Italy is an observational, retrospective, real-world study evaluating dabrafenib plus trametinib in 499 patients with BRAF V600 -mutant stage III unresectable or stage IV melanoma from various sites across Italy...
July 7, 2023: Tumori
https://read.qxmd.com/read/37249074/integrative-analysis-of-tertiary-lymphoid-structures-and-immune-microenvironment-in-patients-with-esophageal-carcinoma
#48
JOURNAL ARTICLE
Yuanshan Yao, Haojie Xuan, Jing Wang, Libao Gong, Wen Gao
BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is one of the most common upper gastrointestinal malignancies worldwide. Tertiary lymphoid structures (TLS) are tumor-infiltrating immune cells aggregates coupled with stromal cells which are similar to secondary lymphoid organs. The objective of this study is to explore the predictive effects of two common genes associated with TLS models on prognosis and immunotherapy effects in ESCC patients. METHODS: Clinical information for ESCC patients in the TCGA(The Cancer Genome Altas) cohort and GSE 53625 were collected...
May 30, 2023: Tumori
https://read.qxmd.com/read/37154050/end-of-life-transfusion-support-at-hospice-and-pediatric-oncology-unit-bridging-the-gap-between-benefits-and-therapeutic-alliance
#49
JOURNAL ARTICLE
Olga Nigro, Marta G Podda, Federico Pellegatta, Elisabetta Schiavello, Carlo A Clerici, Igor Catalano, Giovanna Visconti, Marco Albarini, Roberto Luksch, Monica Terenziani, Andrea Ferrari, Michela Casanova, Veronica Biassoni, Cristina Meazza, Filippo Spreafico, Giovanna Gattuso, Giovanna Sironi, Nadia Puma, Luca Bergamaschi, Stefano Chiaravalli, Maura Massimino
OBJECTIVES: Although transfusion support is commonly used in oncological palliative care, there is still a paucity of literature. We examined the transfusion support provided in the terminal stage of the disease and compared the approach at a pediatric oncology unit and a pediatric hospice. CASE DESCRIPTION: This case series analyzed patients treated at the Fondazione IRCCS Istituto Nazionale dei Tumori di Milano (INT)'s pediatric oncology unit who died between January 2018 and April 2022...
May 8, 2023: Tumori
https://read.qxmd.com/read/37114926/oral-vinorelbine-in-young-patients-with-desmoid-type-fibromatosis
#50
JOURNAL ARTICLE
Laure Kornreich, Daniel Orbach, Nayla Nicolas, Hervé J Brisse, Pablo Berlanga, Anne-Sophie Defachelles, Ludovic Mansuy, Cécile Verite, Laure Saumet, Marie Karanian, Nadège Corradini
BACKGROUND: Desmoid-type fibromatosis are rare intermediate tumors in children and adolescents. Owing to local aggressiveness and relapse, systemic treatment for symptomatic advanced or progressive forms is recommended. Following promising results in adult patients, oral vinorelbine is investigated in young patients. METHODS: A retrospective review of young patients (<25 years old) with advanced or progressive desmoid type fibromatosis treated with oral vinorelbine in eight large centers of the Société Française des Cancers de l'Enfant was performed...
April 28, 2023: Tumori
https://read.qxmd.com/read/37066962/expression-of-concern
#51
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
April 17, 2023: Tumori
https://read.qxmd.com/read/37029687/observational-studies-the-cinderella-of-the-italian-research-system
#52
EDITORIAL
Celeste Cagnazzo, Marco Basiricò, Federica Palermo, Franca Fagioli
Observational trials are crucial to assess the generalizability in the real world of evidence deriving from registration studies. Despite the unquestionable importance of this type of studies, Italian researchers have had to face many obstacles over the years, mainly due to ambiguous definitions and to a complex but at the same time incomplete legislation. The regulatory adjustments to the European Regulation 536/2014 have further complicated the operating and operational framework, making observational research a real "Cinderella" of the Italian system...
April 8, 2023: Tumori
https://read.qxmd.com/read/36964669/blooming-in-the-rain
#53
JOURNAL ARTICLE
Matteo Silva, Massimo Guglielmi, Carlo Alfredo Clerici, Maura Massimino, Andrea Ferrari
No abstract text is available yet for this article.
March 24, 2023: Tumori
https://read.qxmd.com/read/36964667/treating-secondary-malignant-neoplasms-a-burden-of-childhood-cancer-survivors
#54
EDITORIAL
Marta G Podda, Cristina Meazza, Giovanna Gattuso, Giovanna Sironi, Olga Nigro, Luca Bergamaschi, Veronica Biassoni, Michela Casanova, Stefano Chiaravalli, Andrea Ferrari, Roberto Luksch, Nadia Puma, Elisabetta Schiavello, Filippo Spreafico, Paolo Grampa, Siranoush Manoukian, Sabina Vennarini, Paola Collini, Primo A Daolio, Massimiliano Gennaro, Marco Guzzo, Carlo Morosi, Davide Biasoni, Maura Massimino, Monica Terenziani
Each year approximately 35,000 children and adolescents are diagnosed with cancer in Europe. Five-year survival rates have improved and now reach 80% in most European countries, thanks to a combination of chemotherapy, radiotherapy, and surgery. To date, there are more than 44,000 Italians still living several years after being diagnosed with cancer in developmental age. The risk of premature morbidity and mortality for cancer survivors is well known and documented. Approximately 60% of survivors of cancer in childhood and adolescence have at least one chronic health condition in later life, and more than one in four develop severe or life-threatening disorders...
March 24, 2023: Tumori
https://read.qxmd.com/read/36964665/new-perspectives-glioma-in-adult-patients
#55
EDITORIAL
Antonio Silvani
The purpose of this editorial is to consider some of the aspects of the diagnosis and treatment of adult gliomas. These are rare diseases with all their limitations. Innovations in diagnosis and therapy and their constraints are analyzed and compared with the current treatment reality. Aspects affecting these patients' quality of life are highlighted.
March 24, 2023: Tumori
https://read.qxmd.com/read/36964664/advancing-biomarker-development-for-diagnostics-and-therapeutics-using-solid-tumour-cancer-stem-cell-models
#56
REVIEW
Samuel Sherng Young Wang
The cancer stem cell model hopes to explain solid tumour carcinogenesis, tumour progression and treatment failure in cancers. However, the cancer stem cell model has led to minimal clinical translation to cancer stem cell biomarkers and targeted therapies in solid tumours. Many reasons underlie the challenges, one being the imperfect understanding of the cancer stem cell model. This review hopes to spur further research into clinically translatable cancer stem cell biomarkers through first defining cancer stem cells and their associated models...
March 24, 2023: Tumori
https://read.qxmd.com/read/36942401/can-ki-67-predict-radiotherapy-response-in-neuroendocrine-tumors-retrospective-analysis-of-a-monocentric-series-of-patients
#57
JOURNAL ARTICLE
Dario Zerini, Marco Rotondi, Stefania Volpe, Eleonora Pisa, Emanuele Frigo, Cristiana Pedone, Michele Flospergher, Vincenzo Bagnardi, Samuele Frassoni, Cristiana Iuliana Fodor, Francesca Spada, Nicola Fazio, Daniela Alterio, Barbara Alicja Jereczek-Fossa
BACKGROUND: The impact of radiotherapy (RT) in neuroendocrine neoplasms is still unknown, and outcomes could be improved by a better insight in RT response predictors. This retrospective analysis investigates the potential correlation between Ki-67 and RT response to evaluate its role as biological marker of radiosensitivity. MATERIAL AND METHODS: Data from patients treated at an Italian NET-referral center between 2015 and 2020 were retrieved. Inclusion criteria included: histologically-proven diagnosis of NEN, Ki-67 status, indication (symptomatic and/or ablative) and at least one post-RT radiological assessment...
March 20, 2023: Tumori
https://read.qxmd.com/read/36942354/breast-implant-associated-anaplastic-large-cell-lymphoma-evidence-for-an-efficient-diagnostic-workup
#58
JOURNAL ARTICLE
Laura Vittoria, Laura Sala, Valeria Summo, Iolanda Capone, Elena Conca, Martina Toma, Joseph Ottolenghi, Francesca Testa, Umberto Cortinovis, Biagio Paolini, Antonello Cabras, Antonella Aiello, Fabio Bozzi
INTRODUCTION: During the last few years it has been shown that an anaplastic T cell lymphoma can develop as a rare and late sequelae of implant-based breast reconstruction. This malignancy was recognized in the 2017 by WHO and named breast implant associated anaplastic large T cell lymphoma (BIA-ALCL). BIA-ALCL usually presents as abundant effusion around the implant, thus, in addition to cytology smears, its diagnosis also requires immunohistochemistry, T cells clonality and cytometry...
March 20, 2023: Tumori
https://read.qxmd.com/read/36896466/acute-myeloid-leukemia-incidence-transplantation-and-survival-through-italian-administrative-healthcare-data
#59
JOURNAL ARTICLE
Silvia Calabria, Giulia Ronconi, Letizia Dondi, Carlo Piccinni, Antonella Pedrini, Immacolata Esposito, Alice Addesi, Giuseppe Rossi, Felicetto Ferrara, Adriano Venditti, Nello Martini
OBJECTIVE: To identify newly diagnosed patients with acute myeloid leukemia in 2017 treated with intensive chemotherapy or unfit for intensive chemotherapy, and to assess their probability of receiving allogeneic stem cell transplantation and survival, from the Italian National Health Service perspective. PATIENTS AND METHODS: From the Ricerca e Salute database, adults with an in-hospital diagnosis of acute myeloid leukemia (International Classification of Disease-9th version-Clinical Modification code 205...
March 9, 2023: Tumori
https://read.qxmd.com/read/36895186/the-oncohumanities-training-programme-fostering-a-deeper-engagement-and-integration-of-oncology-and-humanities-to-tackle-the-pressing-and-complex-challenges-of-cancer-care
#60
EDITORIAL
Daniele Carrieri, Fedro Alessandro Peccatori, Giovanni Boniolo
'Oncohumanities' is a new field of oncology and humanities which integrates a rich gamut of humanity disciplines and oncological expertise to tackle patients' real needs and priorities. To promote knowledge and awareness on this topic, we propose a training programme that will blend conceptual knowledge underpinning oncology practice with and person-centred care based on the humanisations of care, on empowerment of patients, and on respect for their diversities. Oncohumanities differs from most existing medical humanities training as it is integrated and engaged with oncology (rather than an add-on)...
March 9, 2023: Tumori
journal
journal
21682
3
4
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.